Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date28 Jan 2018 |
100 Clinical Results associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon
0 Patents (Medical) associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon
100 Deals associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon
100 Translational Medicine associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon